initial public offerings (IPOs) trading on American exchanges

Friday, March 11, 2016

Editas Medicine (EDIT) began trading on the Nasdaq on 3 Feb 2016

Editas Medicine is a clinical stage genome editing company. The company is a leader in the nascent field of direct gene editing using CRISPR/Cas9 which has the potential to cure many inherited diseases.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 208
  • Founded in 2013 
  • Headquartered in Cambridge, Massachusetts.
Editas priced 5.9M shares at $16, bottom of indicated range of $16-18.

No comments:

Post a Comment